If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Construction of the plant will commence in 2025 with first production expected to be in 2027
The Notes shall not be offered or sold in India
ALS patients experience neuroinflammation and rapid neurodegeneration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
